Characteristics of SARS-CoV-2 patients dying in Italy

Characteristics of SARS-CoV-2 patients dying in Italy
Report based on available data on May 28th, 2020
1. Sample

The present report describes characteristics of 31,851 SARS-CoV-2 patients dying in Italy.* Geographic distribution across the 19 regions and 2 autonomous provinces of Trento and Bozen is presented in the table below. Data are update to May 28th, 2020.

 

* SARS-CoV-2 related deaths presented in this report are those occurring in patients who test positive for SARS-CoV-2RT by PCR, independently from pre-existing diseases.
2. Demographics
Mean age of patients dying for SARS-CoV-2 infection was 80 years (median 81, range 0-100, IQR 74 -88). Women were 13,042 (40.9%). Figure 1 shows that median age of patients dying for SARS-CoV-2 infection was 20 years higher as compared with the national sample diagnosed with SARS-CoV-2 infection (median age 62 years). Figure 2 shows the absolute number of deaths by age group. Women dying for SARS-CoV-2 infection had an older age than men (median age women 85 - median age men 79).
 

 

3. Pre-existing conditions
Table 1 presents most common comorbidities diagnosed before SARS-CoV-2 infection. Data on diseases were based on chart review and was available on 3,200 patients dying in-hospital for whom it was possible to analyse clinic charts. Mean number of diseases was 3.3 (median 3, SD 1.9). Overall, 4.1% of the sample presented with a no comorbidities, 14.9% with a single comorbidity, 21.5% with 2, and 59.5% with 3 or more.
Before hospitalization, 23% of SARS-CoV-2 positive deceased patients followed ACE-inhibitor therapy and 16% angiotensin receptor blockers-ARBs therapy. This information can be underestimated because data on drug treatment before admission were not always described in the chart.
Table 1. Most common comorbidities observed in SARS-CoV-2 positive deceased patients
 

 

6. Acute conditions
Acute Respiratory Distress syndrome was observed in the majority of patients (96.9% of cases), followed by acute renal failure (22.3%). Superinfection was observed in 12.6% and acute cardiac injury in 10.8% of cases.
7. Treatments
Antibiotics were used by 86% of patients during hospital stay, while less used were antivirals (59%) and corticosteroids (38%). Concomitant use of these 3 treatments was observed in 22.7% of cases.
Out of SARS-CoV-2 positive deceased patients, 4.0% were treated with Tocilizumab during hospitalization.
Source:
https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_28_May_2020.pdf
Characteristics of SARS-CoV-2 patients dying in ItalyReport based on available data on May 2 8th, 2020
*Note:
I do not have everything included from the above pdf file, see above link
31851 died up to May 8th 2020
Of whom 4 were 9 years old or younger. That's 0.0125584754011% of the above figure
In the age group 10 to 19 nobody died
13 died in the age group of 20-29  That's 0.0408150450535% of the above figure

Italy did not use HCQ to my knowledge.
Could have prevented most deaths nor were the vulnerable protected.